


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

1. (currently amended) An imide-substituted pyridylalkane, alkene and alkine acid amide of formula (I)



wherein the substituents have the following meanings:

R^1 is selected from hydrogen, halogen, cyano, alkyl, alkenyl, alkynyl, tri-fluoromethyl, cycloalkyl, hydroxyalkyl, hydroxy, alkoxy, cycloalkyloxy, aralkyloxy ~~such as benzyloxy~~, alkanoyloxy, alkylthio, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, carboxy, aryl ~~such as phenyl~~, aryloxy ~~such as phenoxy~~, arylthio ~~such as phenylthio~~, heteroaryloxy ~~such as pyridyloxy~~, heteroarylthio ~~such as pyridylthio~~, and NR^4R^5 , whereby

R^4 and R^5 are selected independently from each other from hydrogen, alkyl, alkenyl, alkynyl, aralkyl ~~such as benzyl~~ and aryl ~~such as phenyl~~;

R^2 is selected from hydrogen, halogen, cyano, alkyl, trifluoromethyl, hydroxy, alkoxy and aralkyloxy ~~such as benzyloxy~~;

R³ is selected from
hydrogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy and aryloxy ~~such as benzyloxy~~;

k is 0 or 1,

A is selected from
alkylene, optionally substituted one to three-fold by alkyl, hydroxy, alkoxy, fluorine, or
aryl ~~such as phenyl~~,
alkylene, wherein a methylene unit is isosterically replaced by O, S, **NR⁶**, CO, SO or
SO₂, whereby, with the exception of CO, the isosteric substitution cannot be adjacent
to the amine group and **R⁶** is selected from hydrogen, alkyl, alkenyl, acyl ~~or~~ and
alkanesulfonyl;

1,2-cyclopropylene;

alkenylene, optionally substituted once or twice by alkyl, hydroxy, alkoxy, fluorine,
cyano or aryl ~~such as phenyl~~;

alkadienylene, optionally substituted once or twice by alkyl, fluorine, cyano or aryl-
~~such as phenyl~~;


hexatrienylene, optionally substituted by C₁-C₃-alkyl, fluorine, cyano or phenyl; and

ethynylene;

D is selected from
alkylene, optionally substituted once or twice by alkyl, hydroxy, or alkoxy;


alkenylene, optionally substituted once or twice by alkyl, hydroxy, or alkoxy;
alkynylene, optionally substituted once or twice by alkyl, hydroxy, or alkoxy; and
alkylene, alkenylene or alkynylene, in which one to three methylene units is
isosterically replaced by O, S, **NR⁷**, CO, SO or SO₂, wherein **R⁷** is synonymous with
R⁶, but is selected independently thereof;

E is a cyclic imide of the formula



(E 1)

or



(E 2),

bound over the imide nitrogen atom to D selected from

saturated or unsaturated monocyclic imides with 5 to 7 ring atoms, whereby, aside from the essential imide nitrogen atom, one or two further hetero-atoms can be present selected from N and/or S and/or O in this imide ring;

saturated, unsaturated or aromatic anellated bi-, tri- or tetracyclic imides with 8 to 18 ring atoms of which, aside from the essential imide nitrogen atom, one to three further hetero-atoms can be present selected from N and/or S and/or O;

saturated or unsaturated, bridged bi-, tri- tetra- or pentacyclic imides with 8 to 22 ring atoms of which, aside from the essential imide nitrogen atom, one to three further hetero-atoms can be present selected from N and/or S and/or O;

saturated or unsaturated spirocyclic imides, optionally anellated once or twice and with a total of 9 to 23 ring atoms of which, aside from the essential imide nitrogen

atom, one to three further hetero-atoms can be present selected from N and/or S and/or O;

whereby these cyclic imides can be substituted by one to five of the same or different groups selected independently from each other from

halogen, cyano, alkyl, alkylidene, trifluoromethyl, cycloalkyl, cycloalkylidene, phenylalkyl, phenylalkylidene, diphenylalkyl, diphenylalkylidene, triphenylmethyl, aryl ~~such as phenyl,~~ hydroxy, hydroxyalkyl, alkoxy, alkoxy entirely or partially substituted by fluorine, aralkyloxy ~~such as benzyloxy,~~ aryloxy ~~such as phenoxy,~~ naphthyloxy, mercapto, alkylthio, arylthio ~~such as phenylthio or naphthylthio,~~ heteroarylthio ~~such as pyridylthio,~~ alkanesulfonyl, arylsulfonyl ~~such as phenylsulfonyl or naphthylsulfonyl,~~ heteroarylsulfonyl ~~such as pyridylsulfonyl,~~ sulfo, carboxy, carboxyalkyl, carboxyalkenyl, alkoxycarbonyl, aralkyloxycarbonyl ~~such as benzyloxycarbonyl,~~ nitro, amino, aminoalkyl, mono-alkylamino, di-(alkyl)amino, arylamino ~~such as phenylamino,~~ arylalkylamino ~~such as phenylalkylamino,~~ heteroarylamino ~~such as pyridylamino,~~

saturated or unsaturated, four- to seven-membered heterocycles which can contain one or two hetero-atoms selected from N and/or S and/or O and are either bound directly or bound over a methylene group or a methine group,

monocyclic aromatic five- or six-membered heterocycles which can contain one to three hetero-atoms selected from N and/or S and/or O and are either bound directly or bound over a methylene group or a methine group,

annelated bicyclic, aromatic or partially hydrogenated carbocyclic ring systems with 8 to 12 ring atoms which are either bound directly or bound over a methylene or a methine group,

annelated bicyclic aromatic or partially hydrogenated heterocyclic ring systems with 8 to 12 ring atoms, whereby one to three ring atoms can be selected from N and/or S and/or O and are either bound directly or bound over a methylene or a methine group,

and whereby aryl and heteroaryl residues as substituents of the cyclic imides can be substituted themselves by one to three of the same or different groups selected from


halogen, cyano, alkyl, trifluoromethyl, cycloalkyl, aralkyl ~~such as benzyl~~, aryl ~~such as phenyl~~, hydroxy, hydroxyalkyl, alkoxy, alkoxy entirely or partially substituted by fluorine, aralkyloxy ~~such as benzyloxy~~, aryloxy ~~such as phenoxy~~, mercapto, alkylthio, arylthio ~~such as phenylthio~~, carboxy, carboxyalkyl, carboxyalkenyl, alkoxycarbonyl, aralkyloxycarbonyl ~~such as benzyloxycarbonyl~~, nitro, amino, aminoalkyl, mono-alkylamino, di-(alkyl)amino and, for two adjacent residues, methylenedioxy;

~~their~~ the cis- and trans-isomers, E- and Z-isomers of the above defined compounds, ~~especially in the case that A is a cyclopropane ring or D contains one or more double bonds, including~~ the enantiomers, diastereomers and other isomers of the above defined compounds, and their racemic and/or non-racemic mixtures, and the pure endo- and/or exo-isomers of the above defined compounds in the case that the imide ring system is bicyclic, and their mixtures;

~~their~~ the tautomeric compounds in the ~~optimal~~ optional case that E contains a heterocyclic aromatic ring with simultaneous substitution by free hydroxy, mercapto or amino groups; ~~and~~ or the

acid addition salts hydrate or solvate of the above defined compounds ~~including their hydrates and solvates.~~

2. (currently amended) An imide-substituted pyridylalkane, pyridylalkene and pyridylalkine acid amide of formula (I)



wherein the substituents have the following meanings:

R^1 is selected from

hydrogen, halogen, cyano, C₁-C₆-alkyl, C₃-C₆-alkenyl, C₂-C₆-alkinyl, trifluoromethyl, C₃-C₈-cycloalkyl, C₁-C₆-hydroxyalkyl, hydroxy, C₁-C₆-alkoxy, C₃-C₈-cycloalkyloxy, benzyloxy, C₁-C₇-alkanoyloxy, C₁-C₆-alkylthio, C₂-C₇-alkoxycarbonyl, aminocarbonyl, C₂-C₇-alkylaminocarbonyl, C₃-C₁₃-dialkylaminocarbonyl, carboxy, phenyl, phenoxy, phenylthio, pyridyloxy, pyridylthio, and NR⁴R⁵, whereby

R⁴ and R⁵ are selected independently from each other from hydrogen, C₁-C₆-alkyl, C₃-C₆-alkenyl, C₃-C₆-alkinyl, benzyl and phenyl;

R² is selected from hydrogen, halogen, cyano, C₁-C₆-alkyl, trifluoromethyl, hydroxy, C₁-C₆-alkoxy and benzyloxy;

R³ is selected from hydrogen, C₁-C₆-alkyl, C₃-C₆-alkenyl, C₃-C₆-alkinyl, hydroxy, C₁-C₆-alkoxy and benzyloxy;

k is 0 or 1,

A is selected from C₁-C₆-alkylene, optionally substituted one to three-fold by C₁-C₃-alkyl, hydroxy, C₁-C₃-alkoxy, fluorine, or phenyl;

C₂-C₆-alkylene, in which a methylene unit is isosterically replaced by O, S, NR⁶, CO, SO or SO₂, whereby, with the exception of CO, the isosteric substitution cannot be adjacent to the amide group and R⁶ is selected from hydrogen, C₁-C₆-alkyl, C₃-C₆-alkenyl, C₁-C₆-acyl or C₁-C₆-alkanesulfonyl;

1,2-cyclopropylene;

C₂-C₆-alkenylene, optionally substituted once or twice by C₁-C₃-alkyl, hydroxy, C₁-C₃-alkoxy, fluorine, cyano or phenyl;

C₄-C₆-alkadienylene, optionally substituted once to twice by C₁-C₃-alkyl, fluorine, cyano or phenyl;

1,3,5-hexatrienylene, optionally substituted by C₁-C₃-alkyl, fluorine, cyano or phenyl;
and

ethynylene;

D is selected from


C₂-C₁₀-alkylene, optionally substituted once or twice by C₁-C₆-alkyl, hydroxy, or C₁-C₆-alkoxy;

C₄-C₁₀-alkenylene, optionally substituted once or twice by C₁-C₆-alkyl, hydroxy, or C₁-C₆-alkoxy;


C₄-C₁₀-alkynylene, optionally substituted once or twice by C₁-C₆-alkyl, hydroxy, or C₁-C₆-alkoxy; and

C₂-C₁₀-alkylene, C₄-C₁₀-alkenylene or C₄-C₁₀-alkynylene, in which one to three methylene units is isosterically replaced by O, S, NR⁷, CO, SO or SO₂, whereby R⁷ is synonymous with R⁶, but is selected independently thereof;

E is a cyclic imide of the formula



or



bound over the imide nitrogen atom to D selected from

saturated or unsaturated monocyclic imides with 5 to 7 ring atoms of which, aside from the essential imide nitrogen atom, one or two further hetero-atoms can be present selected from N and/or S and/or O;

saturated, unsaturated or aromatic anellated, bi-, tri- or tetracyclic imides with 8 to 18 ring atoms of which, aside from the essential imide nitrogen atom, one to three further hetero-atoms can be present selected from N and/or S and/or O;

saturated or unsaturated, bridged bi-, tri- tetra- or pentacyclic imides with 8 to 22 ring atoms of which, aside from the essential imide nitrogen atom, one to three further hetero-atoms can be present selected from N and/or S and/or O;

saturated or unsaturated spirocyclic imides, optionally anellated once or twice and with a total of 9 to 23 ring atoms of which, aside from the essential imide nitrogen atom, one to three further hetero-atoms can be present selected from N and/or S and/or O;

whereby these cyclic imides can be substituted by one to five of the same or different groups selected independently from each other from

halogen, cyano, C₁-C₆-alkyl, C₁-C₆-alkylidene, trifluoromethyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkylidene, phenyl-C₁-C₃-alkyl, phenyl-C₁-C₃-alkylidene, diphenyl-C₁-C₃-alkyl, diphenyl-C₁-C₃-alkylidene, triphenylmethyl, phenyl, hydroxy, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₁-C₆-alkoxy entirely or partially substituted by fluorine, benzyloxy, phenoxy, naphthyloxy, mercapto, C₁-C₆-alkylthio, phenylthio, naphthylthio, pyridylthio, C₁-C₆-alkanesulfonyl, phenylsulfonyl, naphthylsulfonyl, pyridylsulfonyl, sulfo, carboxy, C₂-C₇-carboxyalkyl, C₂-C₇-carboxyalkenyl, C₂-C₇-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, C₁-C₆-aminoalkyl, mono-C₁-C₆-alkylamino, di-(C₁-C₆-alkyl)amino, phenylamino, phenyl-C₁-C₃-alkylamino, pyridylamino,

Reply to Office Action dated August 3, 2005
Application No. 09/595,218

saturated or unsaturated, four- to seven-membered heterocycles which can contain one or two hetero-atoms selected from N and/or S and/or O and are either bound directly or bound over a methylene group or a methine group,

monocyclic aromatic five- or six-membered heterocycles which can contain one to three hetero-atoms selected from N and/or S and/or O and are either bound directly or bound over a methylene group or a methine group,

annelated bicyclic, aromatic or partial hydrogenated carbocyclic ring systems with 8 to 12 ring atoms which are either bound directly or bound over a methylene or a methine group,

annelated bicyclic aromatic or partially hydrogenated heterocyclic ring systems with 8 to 12 ring atoms, whereby one to three ring atoms can be selected from N and/or S and/or O and are either bound directly or bound over a methylene or a methine group,

and whereby aryl and heteroaryl residues as substituents of the cyclic imides can be substituted themselves by one to three of the same or different groups selected from

halogen, cyano, C₁-C₆-alkyl, trifluoromethyl, C₃-C₈-cycloalkyl, benzyl, phenyl, hydroxy, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₁-C₆-alkoxy entirely or partially substituted by fluorine, benzyloxy, phenoxy, mercapto, C₁-C₆-alkylthio, phenylthio, carboxy, C₂-C₇-carboxyalkyl, C₂-C₇-carboxyalkenyl, C₂-C₇-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, C₁-C₆-aminoalkyl, mono-C₁-C₆-alkylamino, di-(C₁-C₆-alkyl)amino and, for two adjacent residues, methylenedioxy;

~~their~~ the cis- and trans-isomers, E- and Z-isomers of the above defined compounds, ~~especially in the case that A is a cyclopropane ring or D contains one or more double bonds, including~~ the enantiomers, diastereomers and other isomers of the above defined compounds, and ~~their~~ the racemic and/or non-racemic mixtures, and the pure endo- and/or exo-isomers of the above defined compounds in the case that the imide ring system is bicyclic, and ~~their~~ the mixtures;

~~their~~ the tautomeric compounds in the ~~optimal~~ optional case that E contains a heterocyclic aromatic ring with simultaneous substitution by free hydroxy, mercapto or amino groups; ~~and~~

Reply to Office Action dated August 3, 2005
Application No. 09/595,218

~~the corresponding or~~ a acid addition salts of the above defined compounds including their hydrates and or solvates of the above defined compounds.

3. (currently amended) The compound according to claim 1 or 2,

wherein the substituents have the following meanings:

R¹ is selected from
hydrogen, halogen, cyano, C₁-C₆-alkyl, trifluoromethyl, ethinyl, hydroxy, C₁-C₄-alkoxy, benzyloxy, C₁-C₄-alkylthio, C₂-C₅-alkoxycarbonyl, aminocarbonyl, C₃-C₉-dialkylaminocarbonyl, carboxy, phenoxy, phenylthio and pyridyloxy;

R² is selected from
hydrogen, fluorine, chlorine, bromine, C₁-C₄-alkyl, trifluoromethyl, hydroxy, C₁-C₄-alkoxy;

R³ is selected from
hydrogen, C₁-C₃-alkyl, allyl, hydroxy, C₁-C₃-alkoxy and benzyloxy;

k is 0 or 1,

A is selected from
C₁-C₆-alkylene, optionally substituted once or twice by C₁-C₃-alkyl, hydroxy, fluorine or phenyl;

C₂-C₆-alkylene, wherein a methylene unit is isosterically replaced by O, S, NH, N(CH₃) or CO, whereby, with the exception of CO, the isosteric substitution cannot be adjacent to the amide group; and

1,2-cyclopropylene;

C₂-C₆-alkenylene, optionally substituted once or twice by C₁-C₃-alkyl, phenyl, hydroxy and/or fluorine;

C₄-C₆-alkadienylene, optionally substituted once to twice by methyl or fluorine;

1,3,5-hexatrienylene, optionally substituted by methyl or fluorine; and

ethynylene

D is selected from

C₂-C₈-alkylene, optionally substituted once or twice by C₁-C₃-alkyl or hydroxy;

C₄-C₈-alkenylene, optionally substituted once or twice by C₁-C₃-alkyl or hydroxy;

C₄-C₈-alkynylene, optionally substituted once or twice by C₁-C₃-alkyl or hydroxy;
and

C₂-C₈-alkylene, C₄-C₈-alkenylene or C₄-C₈-alkynylene, wherein one to three methylene units are isosterically replaced by O, S, NH, N(CH₃), N(COCH₃), N(SO₂CH₃), CO or SO₂;

E is selected from

saturated or unsaturated monocyclic imides with 5 to 7 ring atoms, ~~for example, of pyrrol-2,5-dione, pyrrolidin-2,5-dione, imidazolidin-2,4-dione, oxazolidin-2,4-dione, thiazolidin-2,4-dione, imidazolidin-2,4,5-trione, piperidin-2,6-dione, 3H-pyridin-2,6-dione, piperazin-2,6-dione, morpholin-3,5-dione, azepin-2,7-dione, 3,6-dihydroazepin-2,7-dione, hexahydroazepin-2,7-dione, hexahydro-1,3-diazepin-2,4-dione, hexahydro-1,4-diazepin-2,7-dione, 3,7-dihydro-1,2,5-triazepin-4,6-dione, hexahydro-1,2,5-triazepin-4,6-dione,~~

saturated, unsaturated or aromatic anellated bicyclic imides, ~~for example, pyrrolo[3,4-e]pyrrol-1,3-dione, dihydropyrrolo[3,4-e]pyrrol-1,3-dione, tetrahydropyrrolo[3,4-e]pyrrol-1,3-dione, tetrahydropyrrolo[1,2-e]imidazol-1,3-dione, thieno[2,3-e]pyrrol-4,6-dione, thieno[3,4-e]pyrrol-4,6-dione, furo[3,4-e]pyrrol-4,6-dione, pyrrolo[3,4-d]thiazol-4,6-dione, isoindol-1,3-dione, tetrahydroisoindol-1,3-dione, hexahydroisoindol-1,3-dione, pyrrolo[3,4-b]pyridin-5,7-dione, pyrrolo[3,4-e]pyridin-1,3-dione, pyrrolo[3,4-e]pyridazin-5,7-dione, 1,1-dioxo-benzo[d]isothiazol-3-one,~~

~~dihydropurin-2,6-dione, 4H-isoquinolin-1,3-dione, 5H-[1,7]naphthyridin-6,8-dione, 4H-[2,6]naphthyridin-1,3-dione, 1H-quinazolin-2,4-dione, 1H-pyrido[2,3-d]pyrimidin-2,4-dione, 1H-pyrido[3,4-d]pyrimidin-2,4-dione,~~

~~unsaturated or aromatic anellated tricyclic imides, such as, for example, benzo[4,5]thieno[2,3-c]pyrrol-1,3-dione, thienoisindol-1,3-dione, benzoisindol-1,3-dione, dihydrobenzoisindol-1,3-dione, tetrahydrobenzoisindol-1,3-dione, pyrrolo[3,4-g]quinolin-6,8-dione, tetrahydropyrrolo[3,4-g]quinazolin-6,8-dione, 1,2,4-triazolo[1,2-a]cinnolin-7,9-dione, dihydrocarbolin-1,3-dione, 4H-benzo[h]isoquinolin-1,3-dione, benzo[de]isoquinolin-1,3-dione, dibenzo[e,c]azepin-5,7-dione, 4H-naphtho[1,8-c,d]azepin-1,3-dione,~~

~~unsaturated or aromatic anellated tetracyclic imides, such as, for example, dihydro-4H-acenaphtho-[1,8-a,c]pyrrol-1,3,10-trione, 6H-pyrrolo[3,4-c]carbazol-1,3-dione, dibenzoisindol-1,3-dione, naphthoisindol-1,3-dione, tetrahydronaphthoisindol-1,3-dione, dibenzo[de,h]isoquinolin-1,3-dione, dihydro-12H-2-azapleiaden-1,3-dione, 1H-anthra[1,9-c,d]azepin-2,4-dione, 4H-anthra[9,1-c,d]azepin-1,3-dione,~~

~~saturated or unsaturated, bridged bi-, tri-, tetra- or pentacyclic imides such as, for example, 3-aza-bicyclo[3.2.1]octan-2,4-dione, 3-aza-bicyclo[3.2.1]oct-6-en-2,4-dione, 3-aza-bicyclo[3.2.2]nonan-2,4-dione, 3-aza-bicyclo[3.2.2]non-6-en-2,4-dione, 4-aza-tricyclo[5.2.1.0 2,6]dec-8-en-3,5-dione, 10-oxa-4-aza-tricyclo[5.2.1.0 2,6]dec-8-en-3,5-dione, 4-aza-tricyclo[5.2.2.0 2,6]undecan-3,5-dione, 4-aza-tricyclo[5.2.2.0 2,6]undec-8-en-3,5-dione, 4-aza-benzo[8,9]tricyclo[5.2.2.0 2,6]undecan-3,5-dione, 4-aza-dibenzo[8,9:10,11]tricyclo[5.2.2.0 2,6]undecan-3,5-dione, 5-aza-dibenzo[10,11:12,13]tricyclo[7.2.2.0 2,8]tri-decan-3,5-dione, and~~

~~saturated or unsaturated spirocyclic imides which are optionally benzoanellated once or twice such as 1,3-diazaspiro[4.4]nonan-2,4-dione, 1-thia-3-azaspiro[4.4]nonan-2,4-dione, 1-oxa-3-azaspiro[4.4]nonan-2,4-dione, 1,3,7-triazaspiro[4.4]nonan-2,4-dione, 1-oxa-3,7-diazaspiro[4.4]nonan-2,4-dione, 2,8-diazaspiro[4.5]decan-1,3-dione, 1,3,8-triazaspiro[4.5]decan-2,4-dione, 1-oxa-3,8-diazaspiro[4.5]decan-2,4-dione, 7-azaspiro[4.5]decan-6,8-dione, spiro[dioxoimidazolidin-indanes], spiro[oxoindolin-dioxoimidazolidines], spiro[dioxoimidazolidin-tetrahydronaphthalines],~~

~~spiro[dioxoimidazolidin-piperidines], and spiro[2,6-dioxopiperidin-tetrahydronaphthalines],~~

whereby these cyclic imides can be substituted by one to five of the same or different groups selected independently from each other from

halogen, cyano, C₁-C₄-alkyl, C₁-C₄-alkylidene, trifluoromethyl, C₃-C₈-cycloalkyl, phenyl-C₁-C₃-alkyl, phenyl-C₁-C₃-alkylidene, diphenyl-C₁-C₃-alkyl, diphenyl-C₁-C₃-alkylidene, triphenylmethyl, phenyl, hydroxy, C₁-C₄-hydroxyalkyl, C₁-C₄-alkoxy, C₁-C₄-alkoxy entirely or partially substituted by fluorine, benzyloxy, phenoxy, naphthyloxy, mercapto, C₁-C₄-alkylthio, phenylthio, pyridylthio, C₁-C₄-alkanesulfonyl, phenylsulfonyl, naphthylsulfonyl, pyridylsulfonyl, sulfo, carboxy, C₂-C₇-carboxyalkyl, C₂-C₇-carboxyalkenyl, C₂-C₇-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, C₁-C₄-aminoalkyl, mono-C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino, phenylamino, phenyl-C₁-C₃-alkylamino, pyridylamino,

saturated or unsaturated, four- to seven-membered heterocycles which can contain one or two hetero-atoms selected from N and/or S and/or O,

monocyclic aromatic five- or six-membered heterocycles, which can contain one to three hetero-atoms selected from N and/or S and/or O and are either bound directly or bound over a methylene group or a methine group,

anellated bicyclic, aromatic or partially hydrogenated carbocyclic ring systems with 8 to 11 ring atoms which are either bound directly or bound over a methylene group or a methine group,

anellated bicyclic aromatic or partially hydrogenated heterocyclic rings systems with 8 to 11 rings atoms, whereby one to three ring atoms can be selected from N and/or S and/or O and are either bound directly or bound over a methylene group or a methine group,

and whereby aryl and heteroaryl residues as substituents of the cyclic imides can be substituted themselves by one to three of the same or different groups selected from

halogen, cyano, C₁-C₆-alkyl, trifluoromethyl, C₃-C₈-cycloalkyl, benzyl, phenyl, hydroxy, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₁-C₆-alkoxy entirely or partially substituted by fluorine, benzyloxy, phenoxy, mercapto, C₁-C₆-alkylthio, phenylthio, carboxy, C₂-C₇-carboxyalkyl, C₂-C₇-carboxyalkenyl, C₂-C₇-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, C₁-C₆-aminoalkyl, mono-C₁-C₆-alkylamino, di-(C₁-C₆-alkyl)amino and, for two adjacent residues, methylenedioxy.

4. (currently amended) The compound according to claim 1 or 2, wherein the substituents have the following meanings:

R¹ is selected from
hydrogen, fluorine, chlorine, bromine, methyl, ethyl, trifluoromethyl, hydroxy, C₁-C₄-alkoxy, phenoxy, methylthio, ethylthio, methoxycarbonyl, aminocarbonyl and carboxy;

R² is selected from
hydrogen, chlorine, methyl, hydroxy and methoxy;

R³ is hydrogen;

k is 0,

A is selected from
C₂-C₆-alkylene, optionally substituted once or twice by hydroxy or fluorine;

C₂-C₆-alkylene, in which a methylene unit is isosterically replaced by O, S, or CO, whereby, with the exception of CO, the isosteric substitution cannot be adjacent to the amide group;

C₂-C₆-alkenylene, optionally substituted by methyl and/or fluorine;

C₄-C₆-alkadienylene, optionally substituted by methyl;

ethynylene;

D is selected from

C₂-C₈-alkylene, optionally substituted by methyl or hydroxy;

C₄-C₈-alkenylene, optionally substituted by methyl or hydroxy;

C₄-C₈-alkynylene, optionally substituted by hydroxy;

C₂-C₈-alkylene, C₄-C₈-alkenylene or C₄-C₈-alkynylene, in which a methylene unit is isosterically replaced by O, NH, N(CH₃), or CO, or an ethylene group is isosterically replaced by a group NH-CO and/or CO-NH, or a propylene group is isosterically replaced by a group NH-CO-NH or NH-CO-O and/or O-CO-NH;

E is selected from

~~monocyclic imides such as succinimide, malcinimide, glutarimide, adipinimide, imidazolidindione, imidazolidintrione, thiazolidindione, oxazolidindione, piperazin-2,6-dione, morpholin-3,5-dione, 3,6-dihydroazepin-2,7-dione, hexahydro-1,3-diazepin-2,4-dione, hexahydro-1,4-diazepin-2,7-dione, hexahydro-1,2,5-triazepin-4,6-dione,~~

~~anellated bicyclic imides such as phthalimide, tetra-hydrophthalimide, homophthalimide, pyrrol-3,4-dicarboximide, 2,5-dihydropyrrol-3,4-dicarboximide, thiophen-2,3-dicarboximide, thiophen-3,4-dicarboximide, pyridin-2,3-dicarboximide, pyridin-3,4-dicarboximide, pyridazin-3,4-dicarboximide, 1,1-dioxo-benzo[d]-isothiazol-3-one, isatoic acid imide, 4H-2,6-naphthyridin-1,3-dione, 1H-pyrido[2,3-d]pyrimidin-2,4-dione,~~

~~anellated tricyclic imides such as naphthalin-1,2-dicarboximide, 1,2,3,4-tetrahydronaphthalin-1,2-dicarboximide, naphthalin-2,3-dicarboximide, 1,8-naphthalimide, diphenic acid imide, benzothiophen-2,3-dicarboximide, benzothiophen-4,5-dicarboximide, quinolin-6,7-dicarboximide, quinazolin-6,7-dicarboximide,~~

~~anellated tetracyclic imides such as 7,8-dihydroacenaphthen-2(6h)-on-1,8a-dicarboximide, anthracen-2,3-dicarboximide, anthracen-1,9-dicarboximide, phenanthren-9,10-dicarboximide, 12a,12b-dihydro-12h-2-azapleiaden-1,3-dione, 1H-anthraceno[1,9-c,d]azepin-2,4-dione, carbazol-5,6-dicarboximide,~~

~~bridged polycyclic imides such as cyclopentan-1,3-dicarboximide, cyclohex-2-en-1,4-dicarboximide, bicyclo[2.2.1]-hept-5-en-2,3-dicarboximide, 7-oxa-bicyclo[2.2.1]-hept-5-en-2,3-dicarboximide, bicyclo[2.2.2]-oct-5-en-2,3-dicarboximide, benzobicyclo[2.2.2]-octan-2,3-dicarboximide, dibenzobicyclo[2.2.2]-octan-2,3-dicarboximide, dibenzobicyclo[2.2.2]-octan-2,3-diacetic acid imide and~~

~~spirocyclic imides such as 1,3-diazaspiro[4.4]nonan-2,4-dione, 1-thia-3-azaspiro[4.4]nonan-2,4-dione, 1-oxa-3,7-diazaspiro[4.4]nonan-2,4-dione, 1-oxa-3,8-diazaspiro[4.5]decan-2,4-dione, spiro[dioximidazolidin-indane], spiro[dioximidazolidin-piperidine], spiro[di-oximidazolidin-oxindoline], spiro[dioximidazolidin-tetrahydronaphthaline], and spiro[2,6-dioxopiperidin-tetrahydronaphthaline],~~

whereby these cyclic imides can be substituted by one to five of the same or different groups selected independently from each other from

halogen, cyano, C₁-C₄-alkyl, trifluoromethyl, C₃-C₈-cycloalkyl, hydroxy, C₁-C₄-hydroxyalkyl, C₁-C₄-alkoxy, C₁-C₄-alkoxy entirely or partially substituted by fluorine, benzyloxy, phenoxy, naphthyloxy, C₁-C₄-alkylthio, phenylthio, pyridylthio, C₁-C₄-alkanesulfonyl, phenylsulfonyl, naphthylsulfonyl, pyridylsulfonyl, sulfo, carboxy, C₂-C₇-carboxyalkyl, C₂-C₇-carboxyalkenyl, C₂-C₇-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, C₁-C₄-aminoalkyl, di-(C₁-C₄-alkyl)amino, phenylamino, pyridylamino;

benzyl, benzylidene, phenylethyl, phenylethylidene, phenylpropyl, diphenylmethyl, diphenylmethylen, diphenylethyl, triphenylmethyl;

phenyl, indanyl, indenyl, indenylmethyl, naphthyl, naphthyl-methyl, tetrahydronaphthyl, benzocycloheptenyl, tetrahydrobenzocycloheptenyl;

pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, hexahydroazepinyl, hexahydrodiazepinyl;

furyl, furylmethyl, thienyl, thienylmethyl, oxazolyl, isox-azolyl, thiazolyl, thiazolylmethyl, imidazolyl, oxadiazolyl, pyridyl, pyridylmethyl, pyrazinyl, pyrimidinyl;

benzofuryl, benzofurylmethyl, benzothienyl, benzothienylmethyl, indolyl, indolylmethyl, indolinyl, oxoindolinyl, dioxoindolinyl, benzooxazolyl, oxobenzooxazolyl, benzothiazolyl, benzothiazolylmethyl, oxobenzothiazolyl, benzoimidazolyl, benzoimidazolylmethyl, oxobenzoimidazolyl, indazolyl, oxoindazolyl, benzotriazolyl, oxazolopyridyl, oxazolopyridylmethyl, oxodihydrooxazolopyridyl, thiazolopyridyl, oxodihydrothiazolopyridyl, imidazopyridyl, oxodihydroimidazopyridyl, chromanyl, chromanonyl, oxazolopyridyl, oxazolopyridylmethyl, isoquinolinyl, oxodihydroquinolinyl, tetrahydroquinolinyl, oxotetrahydroquinolinyl, benzodioxanyl, quinazolinyl, benzoazepinyl, tetrahydrobenzoazepinyl, benzodiazepinyl, tetrahydrobenzodiazepinyl, benzoazepinyl, benzothiazepinyl;

and whereby aryl and heteroaryl residues as substituents of the cyclic imides can be substituted themselves by one to three of the same or different groups selected from

halogen, cyano, C₁-C₆-alkyl, trifluoromethyl, C₃-C₈-cycloalkyl, benzyl, phenyl, hydroxy, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₁-C₆-alkoxy entirely or partially substituted by fluorine, benzyloxy, phenoxy, mercapto, C₁-C₆-alkylthio, phenylthio, carboxy, C₂-C₇-carboxyalkyl, C₂-C₇-carboxyalkenyl, C₂-C₇-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, C₁-C₆-aminoalkyl, mono-C₁-C₆-alkylamino, di-(C₁-C₆-alkyl)amino and, for two adjacent residues, and methylenedioxy.

5. (currently amended) The compound according to claim 1 or 2,

wherein the substituents have the following meanings:

R¹ is selected from
hydrogen, fluorine, methyl, trifluoromethyl, ethylthio;

R^2 is hydrogen;

R^3 is hydrogen;

k is 0,

A is selected from
ethylene or butylene, optionally substituted by hydroxy or one or two fluorine atoms,
or

OCH₂, SCH₂,
ethenylene or 1,3-butadienylene;

D is selected from
C₄-C₆-alkylene, optionally substituted by hydroxy;

C₄-C₆-alkenylene;

C₄-C₆-alkynylene; or

C₄-C₆-alkylene, C₄-C₆-alkenylene or C₄-C₆-alkynylene, wherein one or two methylene
units is isosterically replaced by O, NH or CO;

E is selected from
monocyclic imides such as succinimide, maleinimide, glutarimide, imidazolidindione,
imidazolidintrione, thiazolidindione, oxazolidindione, piperazin-2,6-dione,
hexahydrodiazepin-2,7-dione,

anellated bicyclic imides such as phthalimide, homo-phthalimide, pyridin-2,3-
dicarboximide, pyridin-3,4-dicarboximide, isatoic acid imide,

anellated tricyclic imides such as naphthalin-1,2-dicarboximide, naphthalin-2,3-
dicarboximide, 1,8-naphthalimide, diphenic acid imide,

~~anellated tetracyclic imides such as 7,8-dihydroacena[1,8a]naphthen-2(6H)-on-1,8a-dicarboximide, anthracen-2,3-dicarboximide, anthracen-1,9-dicarboximide, phenanthren-9,10-dicarboximide,~~

~~bridged polycyclic imides such as bicyclo[2.2.1]hept-5-en-2,3-dicarboximide, 7-oxabicyclo[2.2.1]hept-5-en-2,3-dicarboximide, benzobicyclo[2.2.2]octan-2,3-dicarboximide, dibenzobicyclo[2.2.2]octan-2,3-dicarboximide, and~~

~~spirocyclic imides such as spiro[dioximidazolidin-indane], spiro[dioximidazolidin-piperidine], spiro[dioximidazolidin-oxindoline] and spiro[dioximidazolidin-tetrahydronaphthaline],~~

whereby these cyclic imides can be substituted by one to four of the same or different groups selected independently from each other from

halogen, C₁-C₄-Alkyl, trifluoromethyl, hydroxy, hydroxymethyl, methoxy, ethoxy, tert-butoxy, trifluoromethoxy, benzyloxy, phenoxy, phenylthio, pyridylthio, phenylsulfonyl, sulfo, carboxy, C₂-C₇-carboxyalkyl, C₂-C₇-carboxyalkenyl, C₂-C₇-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, aminomethyl, dimethylamino, diethylamino, phenylamino, pyridylamino;
benzyl, benzylidene, phenylethyl, naphthylmethyl, diphenylmethyl, diphenylmethylen, triphenylmethyl, phenyl, naphthyl;
pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, hexahydroazepinyl, hexahydrodiazepinyl;
furyl, furylmethyl, thienyl, thienylmethyl, thiazolyl, thiazolylmethyl, pyridyl, pyridylmethyl; benzofuryl, benzothieryl, indolyl, indolylmethyl, oxodihydro-indolyl, benzoimidazolyl, benzoimidazolylmethyl, oxodihydrobenzoimidazolyl, benzooxazolyl, oxodihydrobenzooxazolyl, benzothiazolyl, oxodihydrobenzothiazolyl, quinolinyl, quinolinylmethyl, oxodihydroquinolinyl, isoquinolinyl, oxodihydroisoquinolinyl,

and whereby aryl and heteroaryl residues as substituents of the cyclic imides can be substituted themselves by one to three of the same or different groups selected from

halogen, cyano, C₁-C₆-Alkyl, trifluoromethyl, C₃-C₈-cycloalkyl, benzyl, phenyl, hydroxy, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₁-C₆-alkoxy entirely or partially substituted by fluorine, benzyloxy, phenoxy, mercapto, C₁-C₆-alkylthio, phenylthio, carboxy, C₂-C₇-carboxyalkyl, C₂-C₇-carboxyalkenyl, C₂-C₇-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, C₁-C₆-aminoalkyl, mono-C₁-C₆-alkylamino, di-(C₁-C₆-alkyl)amino and, for two adjacent residues, methylenedioxy.

6. (currently amended) The compound according to claim 1, which is selected from the group consisting of:

N-[4-(2,5-dioxo-3,4-diphenyl-2,5-dihydro-pyrrol-1-yl)-butyl]-3-pyridin-3-yl-acrylamide,

N-[4-(2,6-dioxo-4-phenyl-piperidin-1-yl)-butyl]-3-pyridin-3-yl-acrylamide,

N-[4-(1,3-dioxo-4,5,6,7-tetraphenyl-1,3-dihydro-isoindol-2-yl)-butyl]-3-pyridin-3-yl-acrylamide,

N-[4-(3-benzyl-2,4,5-trioxo-imidazolidin-1-yl)-butyl]-3-pyridin-3-yl-acrylamide,

N-[4-(1,3,10-trioxo-1,4,5,6,10,10a-hexahydro-acenaphtho[1,8a-c]pyrrol-2-yl)-butyl]-3-pyridin-3-yl-acrylamide,

N-[4-(2,5-dioxo-4,4-diphenyl-imidazolidin-1-yl)-butyl]-3-pyridin-3-yl-acrylamide,

N-[4-(2,5-dioxo-3-phenyl-2,5-dihydro-pyrrol-1-yl)-butyl]-3-pyridin-3-yl-acrylamide,

N-[3-(2,5-dioxo-3,4-diphenyl-2,5-dihydro-pyrrol-1-yl)-propyl]-3-pyridin-3-yl-acrylamide,

N-[4-(3-pyridin-3-yl-acroylamino)-butyl]-2,3:5,6-dibenzobicyclo[2.2.2]octan-7,8-dicarboximide,

N-[4-(5-benzyliden-2,4-dioxo-thiazolidin-3-yl)-butyl]-3-pyridin-3-yl-acrylamide,

N-[4-(4-benzyl-2,6-dioxo-piperazin-1-yl)-butyl]-3-pyridin-3-yl-acrylamide,

N-[6-(2,5-dioxo-3,4-diphenyl-2,5-dihydro-pyrrol-1-yl)-hexyl]-3-pyridin-3-yl-acrylamide,

N-[4-(2,5-dioxo-3,4-diphenyl-2,5-dihydro-pyrrol-1-yl)-butyl]-3-pyridin-3-yl-propionamide,

N-[4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyl]-3-pyridin-3-yl-acrylamide,


N-[4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-butyl]-3-(1-oxidopyridin-3-yl)-acrylamide,

N-[6-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexyl]-3-pyridin-3-yl-acrylamide,


N-[2-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-ethyl]-3-pyridin-3-yl-acrylamide, and

N-[4-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-butyl]-3-pyridin-3-yl-acrylamide.

7. (currently amended) Method for the production of compounds according to claim 1 or 2, wherein compounds of formula (I) are synthesized according to method (A) in such a manner that carboxylic acids of formula (II)




wherein R^1 , R^2 , A and k have the meanings according to claim 1 or 2 or their reactive derivatives, especially in form of their activated esters, anhydrides, acid halides (preferably acid chlorides) or simple lower alkyl esters, are reacted with compounds of formula (III)




wherein D, E, and R³ have the meanings according to claim 1 or 2, in form of their free bases or acid addition salts, in a suitable, ~~preferably inert solvent~~, or a mixture of one or more different solvents, at a temperature of -40°C and 180°C, ~~preferably between -10°C and 130°C, especially at the boiling point of the solvent used~~, optionally in the presence of condensation agents and/or presence of an auxiliary base, or

according to the variant pursuant to method (B), compounds of formula (I) are produced in that starting compounds of formula (IV)



wherein R¹, R², R³, A, D and k have the meaning according to claim 1 or 2 which were obtained by reacting carboxylic acids of formula (II) with amino alcohols of formula (VI),



wherein R³ and D have the meaning according to claim 1 or 2 under conditions as they are described for method (A), are reacted with imides of the formula (V)



as starting compounds, wherein E is as defined in claim 1 or 2,

under the conditions of the Mitsunobu-reaction in which both starting compounds (IV) and (V), are combined by means of an organophosphor^{III} compound and an aliphatic azo compound in a redox condensation, preferably in one or more aprotic solvents, especially tetrahydrofuran, and under inert gas with formal emergence of water whereby depending on

the reactivity of the components, the reaction temperature varies in the range of -20°C to 120°C, preferably between -10°C and 80°C, particularly preferably between 0°C and 30°C.

8. (cancel)

9. (cancel)

10. (cancel)

11. (currently amended) A pharmaceutical composition comprising one or more of the compounds according to claim 1 or 2 as active ingredient(s) optionally in connection with a pharmaceutically acceptable carrier, next to toxicologically safe adjuvants, optionally in combination with other active ingredients.

12. (cancel)

13. (currently amended) ~~The pharmaceutical composition according to claim 11A~~
pharmaceutical composition comprising one or more of the compounds according to claim 1
or 2 as active ingredient, optionally in connection with a pharmaceutically acceptable carrier
next to toxicologically safe adjuvants, optionally in combination with other active
ingredients, wherein it is present in a solid, peroral administrable form as a tablet, capsule, coated tablet, optionally as sustained action and/or gastric fluid-resistant preparation or as a liquid, peroral administrable solution, suspension, effervescent tablet, in the form of tabs or sachets, optionally in sustained action form.

14. (currently amended) ~~The pharmaceutical composition according to claim 11A~~
pharmaceutical composition comprising one or more of the compounds according to claim 1
or 2 as active ingredient, optionally in connection with a pharmaceutically acceptable carrier
next to toxicologically safe adjuvants, optionally in combination with other active
ingredients, wherein it is present in the form of a suitable injection or infusion preparation together with suitable pharmaceutically acceptable carriers and adjuvants, optionally in sustained action form and/or as a parenteral depot medicinal form or implant or is used in the form of a concentrate, powder or lyophilisate and the parenteral dilution agent is optionally manufactured in the packaging separately therefrom, such that the mixing of the compounds

contained therein with a common parenterally applicable dilution agent is possible immediately before use.

15. (currently amended) ~~The pharmaceutical composition according to claim 11A~~
pharmaceutical composition comprising one or more of the compounds according to claim 1
or 2 as active ingredient, optionally in connection with a pharmaceutically acceptable carrier
next to toxicologically safe adjuvants, optionally in combination with other active
ingredients, wherein it is present in the form of an inhalation therapeutic agent, ~~for example,~~
~~in the form of a spray optionally~~ together with suitable pharmaceutically acceptable
propellants, carriers and adjuvants.

16. (currently amended) ~~The pharmaceutical composition according to claim 11A~~
pharmaceutical composition comprising one or more of the compounds according to claim 1
or 2 as active ingredient, optionally in connection with a pharmaceutically acceptable carrier
next to toxicologically safe adjuvants, optionally in combination with other active
ingredients, wherein it is present in the form of a transdermal therapeutic system for systemic
treatment.

17. (currently amended) ~~The pharmaceutical composition according to claim 11A~~
pharmaceutical composition comprising one or more of the compounds according to claim 1
or 2 as active ingredient, optionally in connection with a pharmaceutically acceptable carrier
next to toxicologically safe adjuvants, optionally in combination with other active
ingredients, wherein it is present in the form of a gastrointestinal therapeutic system (GITS)
for systemic treatment.

18. (currently amended) ~~The pharmaceutical composition according to claim 11A~~
pharmaceutical composition comprising one or more of the compounds according to claim 1
or 2 as active ingredient, optionally in connection with a pharmaceutically acceptable carrier
next to toxicologically safe adjuvants, optionally in combination with other active
ingredients, wherein it is present in the form of a salve, suspension, emulsion, a balm or
plaster or in the form of an externally applicable solution.

19. (currently amended) ~~The pharmaceutical composition according to claim 15A~~
pharmaceutical composition comprising one or more of the compounds according to claim 1

or 2 as active ingredient(s) optionally in connection with a pharmaceutically acceptable carrier, next to toxicology safe adjuvants, optionally in combination with other active ingredients, wherein it is present in the form of an inhalation therapeutic agent, optionally together with suitable pharmaceutically acceptable propellants, carriers and adjuvants for administration by means of a controlled dosage aerosol or in the form of a dry powder dosage formulation.

20. (currently amended) The pharmaceutical composition according to claim 11, wherein it is present in the form of a rectal, genital, or transurethral administrable emulsions, a solution, a liposomal solution, an implant, suppository or a capsule.

21. (currently amended) ~~The pharmaceutical composition according to claim 11A~~
pharmaceutical composition comprising one or more of the compounds according to claim 1 or 2 as active ingredient, optionally in connection with a pharmaceutically acceptable carrier next to toxicologically safe adjuvants, optionally in combination with other active ingredients, wherein it is present in the form of a composition capable of being applied nasally, otologically or ophthalmologically.

22. (currently amended) ~~The pharmaceutical composition according to one of the claims 11A~~
pharmaceutical composition comprising one or more of the compounds according to claim 1 or 2 as active ingredient, optionally in connection with a pharmaceutically acceptable carrier next to toxicologically safe adjuvants, optionally in combination with other active ingredients, wherein it is present in the form of a buccally applicable form.

23. (currently amended) ~~The pharmaceutical composition according to claim 11A~~
pharmaceutical composition comprising one or more of the compounds according to claim 1 or 2 as active ingredient, optionally in connection with a pharmaceutically acceptable carrier next to toxicologically safe adjuvants, optionally in combination with other active ingredients, wherein a dosage unit for administration contains 0.001 to 1000, 2000, 3000, 4000 or 5000 mg, preferably 0.01 - 100 mg, in a preferred manner 1 - 10 mg, especially 1, 2, 5, 10, 20, 25, 30, 50, 75, 100, 200, 300, 400, 500, 600, or 800 mg single dose active ingredient according to claim 1 or 2.

24. (currently amended) ~~The pharmaceutical composition according to claim 15~~ A pharmaceutical composition comprising one or more of the compounds according to claim 1 or 2 as active ingredient(s) optionally in connection with a pharmaceutically acceptable carrier, next to toxicology safe adjuvants, optionally in combination with other active ingredients, wherein it is present in the form of an inhalation therapeutic agent, optionally together with suitable pharmaceutically acceptable propellants, carriers and adjuvants, wherein the pharmaceutically acceptable carrier and/or diluent is a propellant aerosol.
25. (currently amended) The pharmaceutical composition according to claim 15, wherein the propellant aerosol is tetrafluoroethane and/or heptafluoropropane and/or propane, butane, or dimethyl ether or mixtures thereof.
26. (currently amended) The pharmaceutical composition according to claim 15, wherein the propellant aerosol contains surface active adjuvants.
27. (currently amended) ~~The pharmaceutical composition according to claim 11~~ A pharmaceutical composition comprising one or more of the compounds according to claim 1 or 2 as active ingredient(s) optionally in connection with a pharmaceutically acceptable carrier, next to toxicology safe adjuvants, optionally in combination with other active ingredients, wherein it is present in the form of an inhalation therapeutic agent, optionally together with suitable pharmaceutically acceptable propellants, carriers and adjuvants, wherein it contains glucose and/or lactose as a dry powder dosage formulation.
28. (cancel)
29. (cancel)
30. (currently amended) ~~The pharmaceutical composition according to claim 11~~ A pharmaceutical composition comprising one or more of the compounds according to claim 1 or 2 as cytostatic agent or immunosuppressive agent, in combination with a further cytostatic agent or immunosuppressive agent which is not a compound according to claim 1 or 2, wherein it is present in combination with a further cytostatic agent or immunosuppressive agent, optionally in the form of separate dosage units in the pharmaceutical package.

31. (cancel)

32. (currently amended) A method of treating ~~or diagnosing~~ a human or animal body comprising administering to the human or animal in need thereof an effective amount of one or more of the compounds according to claim 1 or 2, and optionally one or more suitable pharmaceutically acceptable adjuvants and carriers and/or one or more further active ingredients.

33. (cancel)

34. (new) A method of preventing a disease in a human or animal body comprising administering to the human or animal in need thereof an effective amount of one or more of the compounds according to claim 1 or 2, and optionally one or more suitable pharmaceutically acceptable adjuvants and carriers and/or one or more further active ingredients.

35. (new) A method of treating or preventing cancer in a human or animal body comprising administering to the human or animal in need thereof an effective amount of one or more of the compounds according to claim 1 or 2, optionally one or more suitable pharmaceutically acceptable adjuvants and carriers and/or one or more further active ingredients.

36. (new) A method of treating or preventing abnormal cell growth in a human or animal body comprising administering to the human or animal in need thereof an effective amount of one or more of the compounds according to claim 1 or 2, optionally one or more suitable pharmaceutically acceptable adjuvants and carriers and/or one or more further active ingredients.

37. (new) A method of treating or preventing proliferation of metastasis in a human or animal body comprising administering to the human or animal in need thereof an effective amount of one or more of the compounds according to claim 1 or 2, optionally one or more suitable pharmaceutically acceptable adjuvants and carriers and/or one or more further active ingredients.

38. (new) A method of treating or preventing the formation of metastasis in a human or animal body comprising administering to the human or animal in need thereof an effective amount of one or more of like compounds according to claim 1 or 2, optionally one or more suitable pharmaceutically acceptable adjuvants and carriers and/or one or more further active ingredients.

39. (new) A method of immunosuppression in a human or animal body comprising administering to the human or animal in need thereof an effective amount of one or more of the compounds according to claim 1 or 2 optionally one or more suitable pharmaceutically acceptable adjuvants and carriers and/or one or more further active ingredients.